By Adriano Marchese
Purple Biotech shares soared in premarket trading Monday after the company reported positive phase two study results for its pancreatic cancer drug
Shares traded 68% higher at $5.63.
The Rehovot, Israel-based clinical-stage company said it received positive final results for its lead oncology drug CM24, in patients with pancreatic ductal adenocarcinoma.
The results showed clear and consistent improvement across all efficacy endpoints, it said, adding that it is planning to expand its study further.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 02, 2024 08:49 ET (13:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.